Related Experiment Video
Updated: Jun 5, 2025
A 3D System for Culturing Human Articular Chondrocytes in Synovial Fluid
Published on: January 31, 2012
Disease modifying osteoarthritis drug discovery using a temporal phenotypic reporter in 3D aggregates of primary
Maria A Cruz1, Scott Gronowicz1, Makan Karimzadeh1
1Biionix Cluster, Internal Medicine, University of Central Florida College of Medicine, Orlando, Florida, USA.
Abstract:
Our aim was to develop a novel approach to identify disease-modifying drugs for osteoarthritis (OA), focusing on stimulating type II collagen anabolism in chondrocytes. As ELISA or western blot are destructive, laborious and time consuming, primary human chondrocytes expressing Gaussia luciferase under the control of the type II collagen promoter were developed and used. We cultured them in 3D cartilage aggregates under physioxia, to temporally screen a natural product library over 3-weeks. Hit compounds were analyzed for their potential targets in silico, first by structure, then by RNA-Seq. Two hit compounds were then further analyzed using biochemical assays, dose-response curves, and histological analyses to confirm their effects on type II collagen expression and chondrogenesis. Aromoline shows promise as a potential disease modifying compound, demonstrating an increase in type II collagen expression within cartilage sourced from chondrocytes of three distinct donors. Aromoline is a bisbenzylisoquinoline alkaloid that has been studied for its antiproliferative, anti-inflammatory, and antimicrobial properties, and we are the first to explore its effects on chondrocytes and chondrogenesis. In silico analysis revealed the dopamine receptor D4 (DRD4) as a potential target, confirmed by type II collagen upregulation after aromoline treatment and with DRD4-specific agonist ABT-724. This novel approach combining in silico and in vitro methods provides a platform for drug discovery in a challenging and under-researched area. In conclusion, a novel drug (aromoline) and target receptor (DRD4) were identified as stimulating type II collagen, with the future goal of treating or preventing OA.
Insights
A novel drug, aromoline, was identified to stimulate type II collagen production in chondrocytes, offering a new therapeutic avenue for osteoarthritis (OA). This discovery targets the dopamine receptor D4 (DRD4) for disease modification.
Area of Science:
- Biochemistry and Pharmacology
- Biomaterials and Tissue Engineering
Background:
- Osteoarthritis (OA) poses a significant challenge, with a need for disease-modifying drugs that stimulate cartilage repair.
- Current methods for assessing drug efficacy, such as ELISA and western blot, are destructive and time-consuming.
Purpose of the Study:
- To develop a novel, non-destructive screening platform for identifying disease-modifying drugs for OA.
- To identify compounds that stimulate type II collagen anabolism in chondrocytes.
Main Methods:
- Primary human chondrocytes were engineered to express Gaussia luciferase under the type II collagen promoter.
- Cells were cultured in 3D cartilage aggregates under physioxia for a 3-week screening of a natural product library.
- Hit compounds were analyzed using in silico methods (structural and RNA-Seq), biochemical assays, dose-response curves, and histological analyses.
Main Results:
- Aromoline, a bisbenzylisoquinoline alkaloid, demonstrated a significant increase in type II collagen expression in human chondrocytes from multiple donors.
- In silico analysis identified dopamine receptor D4 (DRD4) as a potential target.
- Aromoline's effect on type II collagen was confirmed and mimicked by a DRD4-specific agonist (ABT-724).
Conclusions:
- A novel drug discovery approach combining in silico and in vitro methods was established for OA.
- Aromoline and its target receptor DRD4 were identified as potent stimulators of type II collagen.
- This research provides a promising foundation for developing new treatments to prevent or manage OA.
